TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03657602
Drug: Mirena Intrauterine System
Normalized name: levonorgestrel Intrauterine System [Mirena]
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will be randomly allocated to this intervention
Study: NCT04458259
Drug: PF-07265807
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given 2 weeks on/1 week off
Study: NCT04458259
Drug: Sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC Q3W
Study: NCT04458259
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed per package label starting with 5 mg PO BID
Study: NCT02163005
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
Study: NCT00743977
Drug: Phenazopyridine HCl
Normalized name: phenazopyridine HCl
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tablet in fasting state
Study: NCT03374943
Drug: KB004
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
Study: NCT03136835
Drug: Maternal Hyperoxygenation
Normalized name: undecylenate
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
Study: NCT01954524
Drug: IV bolus injection of Sildenafil
Normalized name: sildenafil Injection
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
Study: NCT00205231
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02325713
Drug: Oral dispersible tablet of praziquantel (ODT-PZQ)
Normalized name: praziquantel Oral Tablet
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
Study: NCT02325713
Drug: ODT-PZQ
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
Study: NCT02325713
Drug: ODT-PZQ
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
Study: NCT02325713
Drug: ODT-PZQ
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
Study: NCT01896557
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
Study: NCT01896557
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
Study: NCT01896557
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
Study: NCT00012181
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02881190
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03194074
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
Study: NCT03194074
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
Study: NCT01340482
Drug: KRN23
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
Study: NCT01265030
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)
Study: NCT00448201
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
Study: NCT00448201
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fludarabine 30 mg/m\^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
Study: NCT00448201
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
Study: NCT06337604
Drug: TNP-2092 capsules
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT06337604
Drug: TNP-2092 capsules placebo
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT01818141
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 125mg by mouth every 6 hours for 10 days
Study: NCT01818141
Drug: Fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fidaxomicin 200mg by mouth every 12 hours for 10 days
Study: NCT06337604
Drug: Rabeprazole sodium enteric-coated tablets
Normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study: NCT01662622
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted.
Study: NCT00943852
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan 100 mg in one of five treatment periods
Study: NCT00943852
Drug: Comparator: isosorbide mononitrate (ISMN)
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose ISMN 60 mg in one of five treatment periods
Study: NCT00943852
Drug: Comparator: losartan + ISMN
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
Study: NCT00943852
Drug: Comparator: losartan + ISMN
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
Study: NCT00000342
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00196989
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01492179
Drug: Intravenous Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
Study: NCT04449380
Drug: Interferon-ß-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
Study: NCT03454841
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
Study: NCT03454841
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
Study: NCT01492179
Drug: Intra-abdominal Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
Study: NCT02564380
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00734591
Drug: Exubera
Normalized name: EXUBERA
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study: NCT00201708
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
Study: NCT00040651
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00040651
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01158287
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03236584
Drug: lamivudine plus adefovir combination
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: continuing lamivudine plus adefovir
Study: NCT03236584
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: switching to tenofovir
Study: NCT00398398
Drug: Capecitabine, Oxaliplatin, Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Study: NCT03215862
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
Study: NCT01172470
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 doses of induction chemotherapy every 2weeks, IV (in the vein)
Study: NCT01172470
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes
Study: NCT01172470
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour.
Study: NCT01500226
Drug: Rolapitant
Normalized name: Rolapitant
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (4 X 50 mg capsule) 200 mg PO
Study: NCT01500226
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg PO
Study: NCT01500226
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg PO
Study: NCT00821951
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg, 300 mg, 400 mg, once per RT fraction
Study: NCT03188328
Drug: AvidinOX
Normalized name: tolnaftate
DrugBank: Avidin (DB15228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AvidinOX vial containing 22.5 mg AvidinOX~+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume
Study: NCT03188328
Drug: 177Lu-ST2210
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Study: NCT05082753
Drug: Ivermectin tablets (3 mg Ivermectin)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Ivermectin tablets were administered orally.
Study: NCT03188328
Drug: 177Lu-ST2210
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Study: NCT03015129
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03015129
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01986270
Drug: Eletriptan 40 mg
Normalized name: eletriptan 40 MG
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg oral
Study: NCT01986270
Drug: Eletriptan 80 mg
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg oral
Study: NCT01986270
Drug: Sumatriptan 25 mg
Normalized name: sumatriptan 25 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg oral
Study: NCT01986270
Drug: Sumatriptan 50 mg
Normalized name: sumatriptan 50 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg oral
Study: NCT03788759
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
Study: NCT03347864
Drug: 68Ga-NOTA-RM26
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
Study: NCT02242097
Drug: ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01021618
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
Study: NCT02548559
Drug: Full-Spectrum Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Full-Spectrum Cannabidiol; total daily dose of 30 mg.
Study: NCT02548559
Drug: Single-Compound Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-Compound Cannabidiol; total daily dose of 30 mg.
Study: NCT01562041
Drug: Ranolazine 500 mg
Normalized name: ranolazine 500 MG
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 500 mg, oral tablet, b.i.d.
Study: NCT01476449
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
Study: NCT00188942
Drug: Fluoxetine+Olanzapine
Normalized name: fluoxetine / olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00188942
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03300505
Drug: ARRx
Normalized name: rituximab-arrx
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously (IV)
Study: NCT03300505
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth (PO)
Study: NCT02412787
Drug: Idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).
Study: NCT02412787
Drug: Elaprase
Normalized name: Elaprase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
Study: NCT00263016
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01254552
Drug: iobitridol
Normalized name: iobitridol
DrugBank: Iobitridol (DB12407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
Study: NCT01254552
Drug: gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Study: NCT00477503
Drug: Gallium-67 Citrate (Ga-67)
Normalized name: Gallium (67 Ga) citrate
DrugBank: Gallium citrate Ga-67 (DB06784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
Study: NCT00477503
Drug: In-111 DTPA (In-111 pentetate)
Normalized name: DTPA
DrugBank: Indium In-111 pentetate (DB09425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
Study: NCT01428375
Drug: (1) Paracetamol injection
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
Study: NCT00978367
Drug: Avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Study: NCT00978367
Drug: Avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Study: NCT00978367
Drug: Avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.